
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Fulvestrant
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : National Cancer Institute
Deal Size : Undisclosed
Deal Type : Funding
Veramorph Receives NCI Grant for Oral Fulvestrant in ER+ Metastatic Breast Cancer
Details : The funding will support the development of Fulvestrant for estrogen receptor positive metastatic breast cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 15, 2025
Lead Product(s) : Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : National Cancer Institute
Deal Size : Undisclosed
Deal Type : Funding
